Page last updated: 2024-11-12

salvicine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

salvicine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10359290
CHEMBL ID	90715
MeSH ID	M0337991

Synonyms (18)

Synonym
CHEMBL90715
8-(3,4-dihydroxy-4-methylpentyl)-3-isopropyl-7-methylnaphthalene-1,2-dione
240423-23-8
J1.185.369B ,
salvicine
AC-25027
DTXSID50438718
AKOS025401738
8-(3,4-dihydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
1,2-naphthalenedione, 8-(3,4-dihydroxy-4-methylpentyl)-7-methyl-3-(1-methylethyl)-
72F2HK78GM ,
sarubicin
(+/-)-salvicine
4,5-seco-5,10-friedo-abieta-3,4-dihydroxy-5(10),6,8,13-tetraene-11,12-dione
unii-72f2hk78gm
8-(3,4-dihydroxy-4-methylpentyl)-7-methyl-3-(1-methylethyl)-1,2-naphthalenedione
3-isopropyl-7-methyl-8-(3,4-dihydroxy-4-methylpentyl)-1,2-dihydronaphthalene-1,2-dione
FS-7572

Research Excerpts

Overview

Salvicine is a diterpenoid quinone derived from a traditional Chinese medication that has been shown to possess potent antitumor effects. It was demonstrated to stabilize the DNA topoisomerase II cleavage complex in vitro and in vivo.

Excerpt	Reference	Relevance
"Salvicine is a pharmacologically active derivative from Chinese medicinal plant Salvia prionitis Hance (Labiatae). "	( Anti-angiogenic activity of salvicine. Chen, Y; Qing, C; Wang, L; Zhang, Y, 2013)	2.13
"Salvicine is a novel topoisomerase II inhibitor possessing significant antitumor activity, both in vitro and in vivo. "	( Down-regulation of telomerase activity via protein phosphatase 2A activation in salvicine-induced human leukemia HL-60 cell apoptosis. Ding, J; Jiang, JF; Liu, WJ; Xiao, D, 2002)	1.98
"Salvicine is a diterpenoid quinone derived from a traditional Chinese medication that has been shown to possess potent in vitro and in vivo antitumor effects. "	( Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line. Ding, J; Han, JX; Miao, ZH; Tong, LJ; Zhang, JS, 2004)	2.09
"Salvicine is a novel non-intercalative topoisomerase II poison."	( DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells. Ding, J; Huang, M; Lu, HR; Meng, LH; Miao, ZH; Zhu, H, 2005)	1.27
"Salvicine is a novel DNA topoisomerase II inhibitor with potent anticancer activity. "	( Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Chen, H; Ding, J; Lang, JY; Li, MH; Lin, LP; Waalkes, MP; Zhang, JS; Zhang, XW; Zhang, YX; Zhou, J, 2005)	2.07
"Salvicine is a novel diterpenoid quinone compound obtained by structural modification of a natural product lead isolated from a Chinese herb with potent growth inhibitory activity against a wide spectrum of human tumor cells in vitro and in mice bearing human tumor xenografts. "	( Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Ding, J; Meng, LH, 2007)	3.23
"Salvicine is a novel diterpenoid quinone derivative possessing strong antitumor activities and was demonstrated to stabilize the DNA topoisomerase II (Topo II) cleavage complex in vitro and in vivo. "	( Induction of bulk and c-myc P2 promoter-specific DNA damage by an anti-topoisomerase II agent salvicine is an early event leading to apoptosis in HL-60 cells. Ding, J; Meng, L, 2001)	1.97

Treatment

Excerpt	Reference	Relevance
"Salvicine treatment resulted in HL-60 cell apoptosis and down-regulation of telomerase activity in a time- and concentration-dependent manner."	( Down-regulation of telomerase activity via protein phosphatase 2A activation in salvicine-induced human leukemia HL-60 cell apoptosis. Ding, J; Jiang, JF; Liu, WJ; Xiao, D, 2002)	1.26

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (90)

Assay ID	Title	Year	Journal	Article
AID110135	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg (day 7); 21.6/22.9	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123718	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123716	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg i.p. (day 9)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114878	In vivo inhibitory activity against human lung adenocarcinoma xenograft LAX-83 in mice at a dose of 10 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123715	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg (day 6)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114875	In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 30 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110134	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg i.p. (day7); 20.9/26.1	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123841	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123719	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx9) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115702	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx9) administered i.p.; 6/6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115694	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 6/6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114886	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 15 mg/kg (day 6)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110112	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 22.3/21.2	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123843	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114881	In vivo inhibitory activity against human lung adenocarcinoma xenograft LAX-83 in mice at a dose of 30 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115701	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 6/6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110121	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg (day 7); 21.4/24.8	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114892	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 7.5 mg/kg i.p. (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114893	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 7.5 mg/kg (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115690	Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 5/5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109981	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 24.8/26.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109984	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg i.p. (day 9); 19.9/18.3	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123712	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115698	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 6/6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123839	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114882	In vivo inhibitory activity against murine Lewis lung cancer at a dose of 15 mg/kg i.p. (day10)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115697	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 4/4	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114880	In vivo inhibitory activity against human lung adenocarcinoma xenograft LAX-83 in mice at a dose of 20 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123840	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx9) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123723	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg i.p. (day 10)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123846	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg i.p. (day 10)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID117386	In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 10 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110119	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg (day 10) administered i.p.; 19.2/20.5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110127	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 22.8/23.2	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115689	Compound was tested in vivo for antitumor activity against murine S-180 sarcoma and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg (day 7) administered i.p.; 10/10	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109980	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 22.0/22.6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115703	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg (day 7) administered i.p.; 10/10	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123845	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110113	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 22.3/23.5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114874	In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 20 mg/kg (Q2dx9) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114883	In vivo inhibitory activity against murine Lewis lung cancer at a dose of 37.5 mg/kg i.p. (day10)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114890	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 3.75 mg/kg i.p. (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110122	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg i.p. (day7); 21.0/26.9	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109983	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg i.p. (day 9); 19.0/16.6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115695	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx9) administered i.p.; 6/6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114885	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 15 mg/kg (day 6)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110126	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 21.5/21.2	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID117387	In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 10 mg/kg (Q2dx9) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109978	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 19.6/21.3	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109979	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 21.8/19.5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115692	Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 5/5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115700	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 4/4	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123722	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110128	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx9) administered i.p.; 21.5/21.9	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110120	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg (day 7); 21.4/23.8	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID117390	In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 20 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110125	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 19.8/19.5 0.44	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110131	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg (day 7); 21.3/23.1	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109982	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx9) administered i.p.; 21.1/24.6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115696	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 15.0 mg/kg (day 6) administered i.p.; 10/10	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110114	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 24.5/25.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115691	Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 5/5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID150674	In vitro cytotoxic activity against P388 mouse leukemia cell line by MTT assay (microculture terazolium colorimetric)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123844	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg i.p. (day 10)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114891	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 7.5 mg/kg (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110123	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg i.p. (day 10); 20.1/22.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123714	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg i.p. (day 9)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109987	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg (day 6); 21.7/21.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110132	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg i.p. (day 10); 19.1/19.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114877	In vivo inhibitory activity against human lung adenocarcinoma xenograft LAX-83 in mice at a dose of 10 mg/kg (Q2dx10) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID200978	In vitro cytotoxic activity against SPC-A4 lung cancer solid tumor cell line by MTT assay (microculture terazolium colorimetric)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115699	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx9) administered i.p.; 6/6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID115693	Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 4/4	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109985	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg i.p. (day 6); 20.9/22.8	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123838	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.75 mg/kg i.p. (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114887	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 15 mg/kg i.p. (day 6)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110129	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 22.2/19.6	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114889	In vivo inhibitory activity against murine S-180 sarcoma at a dose of 3.75 mg/kg (day 7)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114884	In vivo inhibitory activity against murine Lewis lung cancer at a dose of 7.5 mg/kg i.p. (day10)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID201320	In vitro cytotoxic activity against SGC-7901 stomach cancer solid tumor cell line by MTT assay (microculture terazolium colorimetric)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110115	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx9) administered i.p.; 21.4/23.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109986	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg (day 6); 21.4/20.4	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID114876	In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 30 mg/kg (Q2dx9) administered i.p.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110110	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 18.5/19	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110111	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 20 mg/kg (Q2dx10) administered i.p.; 19.5/19.9	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID109977	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 10 mg/kg (Q2dx10) administered i.p.; 18.7/16.0	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID81465	In vitro cytotoxic activity against HL-60 human leukemia cell line by MTT assay (microculture terazolium colorimetric)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110133	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 7.5 mg/kg i.p. (day 10); 19.8/19.5	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123713	Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 15 mg/kg (day 6)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID110124	Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 30 mg/kg (Q2dx10) administered i.p.; 18.5/14.7	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (8.70)	18.2507
2000's	20 (86.96)	29.6817
2010's	1 (4.35)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	21.45 (24.57)
Research Supply Index	3.18 (2.92)
Research Growth Index	5.33 (4.65)
Search Engine Demand Index	18.60 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (21.45)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.35%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (95.65%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2	1	mitomycin	alkylating agent; antineoplastic agent
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.43	2	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
deoxycytidine [no description available]	2.02	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
etoposide [no description available]	3.11	5	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.02	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.01	1	actinomycin	mutagen
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	5.6	23
lysophosphatidic acid lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.	2.02	1	1-acyl-sn-glycerol 3-phosphate
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.03	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	2.01	1	ketal

Condition	Relationship Strength	Studies
Adenocarcinoma, Basal Cell [description not available]	2.72	3
Cancer of Lung [description not available]	2.95	4
Angiogenesis, Pathologic [description not available]	2.08	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	7.72	3
Lung Neoplasms Tumors or cancer of the LUNG.	2.95	4
Leucocythaemia [description not available]	2.01	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	7.01	1
Invasiveness, Neoplasm [description not available]	2.02	1
Breast Cancer [description not available]	2.71	3
Breast Neoplasms Tumors or cancer of the human BREAST.	2.71	3
Experimental Mammary Neoplasms [description not available]	2.02	1
Cancer of Pancreas [description not available]	2.02	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.02	1
Carcinoma, Anaplastic [description not available]	2.04	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.04	1
Cancer of Stomach [description not available]	2	1
Granulocytic Leukemia, Chronic [description not available]	2	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2	1

chemdatabank.com